1. In Vivo
  2. >>Leadership

Gaming Whiz Brings AI Smarts To Drug Discovery

Machine Learning Opens Windows On New Disease Targets

 
• By Eleanor Malone

GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.

Video game. Elements and objects for computer game. Template for construction game level. Background for arcade game.
Gaming expert Noor Shaker doubles down on drug discovery quest • Source: Shutterstock

Entrepreneur Noor Shaker only moved into health care in 2017, after pursuing an academic career in computer science and artificial intelligence that focused on gaming and adaptive artificial intelligence (AI). She is already making her mark. Her latest start-up, GlamorousAI, was launched into the coronavirus pandemic and quickly established a collaboration with Cardiff University in the UK to design a novel compound to treat COVID-19. The five-person firm is also working on additional projects with academic, biotech and pharma partners. 

“I believe AI can actually change how we do drug discovery in terms of efficiencies and acceleration – bringing cures...

More from Leadership

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.